$0.0 (-1.35%)
| Source | Headline |
|---|---|
|
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies
Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelines Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Numinus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal agencies to accelerate research, access, and regulatory review for psychedelic-based treatments, including psilocybin, ibogaine, MDMA, and LSD. newsfilecorp.com - 2026-04-20 08:30:00 |